These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36609841)

  • 21. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.
    Castle PE; Aslam S; Behrens C
    Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
    Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country.
    Ramírez AT; Sánchez GI; Nedjai B; Agudelo MC; Brentnall AR; Cuschieri K; Castañeda KM; Cuzick J; Lorincz AT;
    Int J Cancer; 2021 Mar; 148(6):1383-1393. PubMed ID: 33006394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
    Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.
    Lindquist S; Kjær SK; Frederiksen K; Ørnskov D; Petersen LK; Munk C; Waldstrøm M
    Acta Obstet Gynecol Scand; 2024 Sep; 103(9):1781-1788. PubMed ID: 39012789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.
    Kelly HA; Chikandiwa A; Sawadogo B; Gilham C; Michelow P; Lompo OG; Omar T; Zan S; Magooa P; Segondy M; Nagot N; Meda N; Delany-Moretlwe S; Mayaud P;
    PLoS Med; 2021 Mar; 18(3):e1003528. PubMed ID: 33661957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
    Dick S; Kremer WW; De Strooper LMA; Lissenberg-Witte BI; Steenbergen RDM; Meijer CJLM; Berkhof J; Heideman DAM
    Gynecol Oncol; 2019 Aug; 154(2):368-373. PubMed ID: 31182225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotyping and Cytology Triage of High-Risk HPV DNA Positive Women for Detection of Cervical High-Grade Lesions.
    El-Zein M; Bouten S; Abdrabo LS; Siblini A; Louvanto K; Franco E; Ferenczy A
    J Low Genit Tract Dis; 2023 Jan; 27(1):12-18. PubMed ID: 36205321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
    Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
    JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.